Peripheral neuropathy can develop gradually, particularly in patients with diabetes, metabolic disease, and other conditions affecting peripheral nerves. One of the challenges for physicians is that early neuropathy may involve small autonomic nerve fibers before more obvious large-fiber abnormalities develop.
SweatC is designed around this clinical principle. By assessing sweat-related electrical properties of the skin, the device can provide information about sudomotor function, which is associated with the activity of sympathetic autonomic small fibers.
For physicians, the value of SweatC is therefore not simply that it produces a numerical result. Its potential value is providing a rapid, non-invasive physiological assessment that can complement conventional neurological evaluation.
What Is SweatC?
SweatC is a sudomotor assessment technology designed to evaluate sweat gland-related function. Sweat glands are innervated by postganglionic sympathetic cholinergic C-fibers. Damage or dysfunction affecting these fibers can alter sweating and may occur as part of peripheral or autonomic neuropathy.
The underlying clinical concept can be summarized as:
Peripheral small-fiber/autonomic dysfunction → altered sudomotor activity → altered skin electrical properties → measurable change → clinical interpretation
This makes sudomotor assessment potentially useful when a physician suspects neuropathy but wants information beyond conventional large-fiber testing.
Why Assess Sudomotor Function?
Traditional nerve conduction studies are valuable for evaluating large peripheral nerve fibers, but they do not comprehensively evaluate small autonomic fibers.
This is important because early peripheral neuropathy can present with symptoms such as:
- Burning feet
- Tingling or prickling
- Altered temperature sensation
- Pain or hypersensitivity
- Abnormal sweating
- Dry skin
- Changes in autonomic function
Research has shown that sudomotor dysfunction can be associated with diabetic peripheral neuropathy and may occur relatively early in the disease process. A literature review of diabetic peripheral neuropathy notes that small-fiber neuropathy can occur during prediabetes and that sudomotor dysfunction is considered an early manifestation of autonomic dysfunction.
Therefore, SweatC can potentially add another physiological dimension to the physician’s assessment.
How SweatC Testing Works
The precise measurement methodology depends on the specific SweatC implementation and should be interpreted according to the manufacturer’s validated protocol.
In general, sudomotor assessment works by measuring electrical properties associated with sweat production at the skin surface.
Simplified workflow
1. Patient preparation
The patient is positioned comfortably and relevant clinical information is recorded.
↓
2. Sensor/electrode contact
The relevant skin surfaces are placed in contact with the device’s measurement interface.
↓
3. Electrical measurement
The system obtains a sweat-related electrical response from the skin.
↓
4. Data processing
The device processes the measured signal and generates quantitative results.
↓
5. Clinical report
Results are presented for physician interpretation.
↓
6. Clinical correlation
The findings are considered alongside symptoms, neurological examination, diabetes status, medication history and other investigations.
The key point is that the measurement is physiological; the diagnosis remains clinical.
SweatC and Peripheral Neuropathy
Peripheral neuropathy is not a single disease. It can result from diabetes, impaired glucose metabolism, nutritional deficiencies, toxic exposures, medications, autoimmune disorders, inherited conditions and other causes.
Sweat testing is particularly relevant when the suspected neuropathy includes small autonomic fibers.
A reduced or abnormal sudomotor response can indicate dysfunction involving the pathway responsible for sweating. It does not, by itself, establish the cause of the abnormality.
This distinction is important in physician interpretation:
Abnormal SweatC result ≠ automatic diagnosis of diabetic neuropathy
Instead:
Abnormal result + symptoms + examination + risk factors + appropriate investigations = stronger clinical assessment
Clinical Evidence for Sudomotor Assessment
Evidence for electrochemical skin-conductance-based sudomotor testing has accumulated over the past decade.
One study involving 55 patients with suspected distal symmetric polyneuropathy and 42 controls found that electrochemical skin conductance was lower in patients with distal symmetric polyneuropathy. Feet conductance and intraepidermal nerve fiber density produced similar areas under the ROC curve in that study—0.761 and 0.752, respectively.
Another study of 47 patients with type 2 diabetes found significantly lower hand and foot electrochemical skin conductance among patients with diabetic peripheral neuropathy. In that study, foot measurements had 70% sensitivity and 53% specificity at the selected cutoff, while hand measurements had 85% sensitivity and 50% specificity.
More recently, a 2026 systematic review of SUDOSCAN studies involving 7,343 participants reported pooled sensitivity of approximately 81% and specificity of approximately 73% for diabetic neuropathy across five studies contributing to quantitative analysis. However, the authors highlighted substantial heterogeneity in diagnostic criteria, thresholds and populations and concluded that standardized thresholds remain a limitation for standalone use.
These data are encouraging, but they also demonstrate why SweatC-type measurements should be positioned as screening or adjunctive information rather than a universal replacement for established neurological testing.
What Does an Abnormal Sweat Result Mean?
Sweat abnormalities can occur when the small autonomic fibers supplying sweat glands are impaired.
In diabetic patients, this may be associated with peripheral or autonomic neuropathy.
The clinical interpretation should consider:
- Reduced sweating
- Excessive sweating
- Dry skin
- Burning or painful feet
- Loss of temperature sensation
- Neuropathic symptoms
- Diabetes duration and glycemic history
- Other metabolic or neurological conditions
A result becomes more meaningful when it agrees with the patient’s clinical presentation.
SweatC Compared With Conventional Neuropathy Testing
| Assessment | Primary information | Main limitation |
| Monofilament | Loss of protective sensation | Less sensitive to early small-fiber dysfunction |
| Vibration testing | Large-fiber sensory function | Does not directly assess sudomotor function |
| Nerve conduction studies | Large peripheral nerve function | Can be normal in predominantly small-fiber disease |
| Skin biopsy | Small-fiber structural density | Invasive and requires specialized analysis |
| QSART | Quantitative sudomotor function | Specialized equipment and expertise |
| SweatC/sudomotor assessment | Sweat-related physiological function | Requires technology-specific interpretation |
QSART has historically been an important reference method for sudomotor evaluation, with older ADA literature reporting sensitivity greater than 75% for detecting distal small-fiber polyneuropathy.
Advantages of SweatC Testing
1. Non-invasive approach
A major practical advantage of sweat-based assessment is that it can provide physiological information without requiring a skin biopsy or needle-based procedure.
2. Rapid clinical workflow
Sudomotor testing can potentially be incorporated into a routine office assessment without the extensive setup required for some specialized autonomic laboratory procedures.
3. Objective measurement
Rather than relying exclusively on subjective descriptions such as “my feet burn,” the physician receives a quantitative physiological measurement.
4. Complementary information
SweatC can potentially complement:
- Neurological examination
- Monofilament testing
- Vibration testing
- Nerve conduction studies
- Metabolic laboratory testing
- Other autonomic tests
5. Potential value in early assessment
Because sudomotor abnormalities may involve small autonomic fibers, the test may provide useful information before more advanced large-fiber abnormalities become apparent.
Limitations and Clinical Considerations
SweatC should not be presented as a definitive standalone diagnostic test.
Measurement variability
Sweating and skin electrical properties can be affected by environmental conditions, skin temperature, hydration and other physiological factors.
Medication effects
Medications affecting autonomic function or sweating may influence measurements and should be considered during interpretation.
Technology-specific thresholds
Different sudomotor technologies do not necessarily use identical methodologies or reference ranges.
Not disease-specific
An abnormal sudomotor result does not automatically identify diabetes as the cause. The physician must investigate the clinical context.
Evidence remains heterogeneous
A 2019 systematic review concluded that electrochemical skin conductance expands the available tools for sudomotor evaluation but emphasized the need to understand its advantages and disadvantages compared with established tests.
A separate systematic review raised more substantial concerns, including inconsistent normative values and insufficient evidence to conclude that electrochemical skin conductance directly measures small-fiber sensory or autonomic function.
These differences in the literature are important. Physicians should use SweatC results according to the validated indications, methodology and reference ranges for the particular device rather than extrapolating from another technology.
Practical Clinical Workflow
A sensible approach is:
Patient at risk
↓
Symptoms / diabetes / neuropathy risk identified
↓
Clinical neurological examination
↓
Assess sensory and autonomic features
↓
SweatC sudomotor assessment when clinically appropriate
↓
Interpret result with clinical findings
↓
Consider additional testing if indicated
↓
Identify underlying cause and establish follow-up
This workflow prevents the common mistake of treating a device measurement as an isolated diagnosis.
Useful Tips for Physicians
Standardize testing conditions.
Consistent preparation and measurement conditions improve comparability.
Review medications.
Document medications that could influence sweating or autonomic function.
Examine the feet.
Sudomotor abnormalities should be considered alongside skin integrity, sensation and other diabetic foot-risk factors.
Do not use a single number in isolation.
Interpret the result in the context of symptoms and examination.
Understand the technology.
Know exactly what SweatC measures, how the result is calculated and what reference population the device uses.
Use complementary testing when necessary.
A patient with significant symptoms and an abnormal result may require additional neurological or autonomic evaluation.
Key Facts
- Sweat glands are controlled by sympathetic postganglionic cholinergic C-fibers.
- Sudomotor dysfunction can occur with diabetic peripheral and autonomic neuropathy.
- Electrochemical skin conductance has been investigated as a rapid, non-invasive approach to sudomotor assessment.
- Published studies have reported associations between reduced conductance and diabetic neuropathy, but diagnostic performance varies considerably.
- A 2026 systematic review found promising pooled diagnostic performance but substantial heterogeneity and a lack of standardized thresholds.
- Sweat testing should complement, rather than automatically replace, clinical neurological assessment.
Mini FAQ
1. Can SweatC diagnose peripheral neuropathy?
SweatC can provide information about sudomotor function that may support the assessment of peripheral or autonomic neuropathy. An abnormal result should not be considered a standalone diagnosis.
2. Why can sweat testing be useful when nerve conduction studies are normal?
Nerve conduction studies primarily evaluate large nerve fibers. Sudomotor testing evaluates a different physiological function involving small autonomic fibers, so the two tests can provide complementary information.
3. Is SweatC useful for diabetic patients?
Potentially. Diabetes is a major clinical setting for evaluating sudomotor and peripheral neuropathy. Research has demonstrated associations between abnormal electrochemical skin conductance and diabetic neuropathy, although performance varies between studies.
4. Does an abnormal SweatC result prove small-fiber neuropathy?
No. It indicates an abnormality in the measured sweat-related physiological response. The finding must be interpreted alongside symptoms, examination findings, risk factors and, when appropriate, additional diagnostic tests.
Conclusion
SweatC represents an approach to assessing sudomotor function as part of peripheral neuropathy evaluation. Its principal clinical advantage is the ability to obtain physiological information through a relatively rapid and non-invasive measurement.
For physicians, the greatest value comes from using SweatC as part of a multimodal neuropathy assessment rather than viewing it as a replacement for neurological examination, nerve conduction studies, skin biopsy or specialized autonomic testing.
The evidence is promising, particularly in diabetes and early neuropathy screening, but published research also demonstrates variability in thresholds and diagnostic performance. Consequently, appropriate patient selection, standardized testing, device-specific interpretation and clinical correlation remain essential.
Used within that framework, SweatC can give clinicians another measurable piece of information when evaluating patients at risk for peripheral, small-fiber or autonomic dysfunction.





